Key Points
- Insider Giles Wilson bought 179 Dr. Martens shares at GBX 84 each, totaling £150.36, following a much larger purchase of 68,313 shares worth £49,185.36 in June.
- Dr. Martens shares opened at GBX 88.62, above their 50-day average of GBX 74.87 and 200-day average of GBX 69.28; the stock’s one-year range is GBX 59.15 to GBX 100.87.
- Analysts maintain a generally positive outlook, with two Buy ratings and one Hold rating, producing a “Moderate Buy” consensus and an average price target of GBX 105.
Dr. Martens plc (LON:DOCS - Get Free Report) insider Giles Wilson bought 179 shares of the company's stock in a transaction dated Tuesday, August 11th. The stock was bought at an average cost of GBX 84 per share, with a total value of £150.36.
Giles Wilson also recently made the following trade(s):
- On Thursday, June 25th, Giles Wilson bought 68,313 shares of Dr. Martens stock. The shares were bought at an average price of GBX 72 per share, with a total value of £49,185.36.
- On Thursday, June 11th, Giles Wilson purchased 202 shares of Dr. Martens stock. The stock was bought at an average cost of GBX 74 per share, for a total transaction of £149.48.
Dr. Martens Price Performance
Shares of DOCS stock opened at GBX 88.62 on Friday. The stock's fifty day simple moving average is GBX 74.87 and its 200 day simple moving average is GBX 69.28. Dr. Martens plc has a one year low of GBX 59.15 and a one year high of GBX 100.87. The firm has a market cap of £848.18 million, a price-to-earnings ratio of 36.92, a P/E/G ratio of 6.40 and a beta of 0.26. The company has a debt-to-equity ratio of 108.85, a current ratio of 2.61 and a quick ratio of 1.13.
Dr. Martens (LON:DOCS - Get Free Report) last released its quarterly earnings data on Tuesday, May 19th. The company reported GBX 4.20 earnings per share (EPS) for the quarter. The firm had revenue of £764.90 million during the quarter. Dr. Martens had a return on equity of 6.89% and a net margin of 3.11%. On average, analysts expect that Dr. Martens plc will post 2.5809394 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
DOCS has been the topic of several research analyst reports. Royal Bank Of Canada reaffirmed a "sector perform" rating and set a GBX 100 price objective on shares of Dr. Martens in a research note on Tuesday, June 2nd. Berenberg Bank cut their target price on shares of Dr. Martens from GBX 114 to GBX 110 and set a "buy" rating for the company in a research note on Tuesday, May 19th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of GBX 105.
Get Our Latest Stock Report on Dr. Martens
About Dr. Martens
(
Get Free Report)
Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.
The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
